Company intelligence / Profile preview

Transwell Biotech Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Completed Phase I clinical trial for TWB-103 for donor site wounds in Taiwan. Currently conducting Phase I/II clinical trials in Taiwan and Japan for TWB-103 in adults with skin graft donor site wounds.

Therapeutic areas: Dermatology
Modalities: Cell therapyExtracellular Vesicles (EVs)Exosomes
Industry: Biotech

Drug pipeline

1 asset

TWB-103

Partnerships

Elanix Biotechnologies AG (Switzerland)

Beyond the preview

Go deeper on Transwell Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transwell Biotech Co., Ltd..

Explore the full profile